Sugi Predict

Sugi Predict / Compounds / SCHEMBL2174420

SCHEMBL2174420

SCHEMBL2174420

CCOC(C)O[C@@H](COS(=O)(=O)c1ccc(C)cc1)CN(Cc1ccccc1)[C@@H](CC(=O)OC)C(=O)OCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.37
▸ POLB P06746 1/20 0.36
▸ CA1 P00915 5/20 0.35
▸ CA2 P00918 5/20 0.35
▸ MAPT P10636 3/20 0.35
▸ TP53 P04637 1/20 0.35
▸ P2RX7 Q99572 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ OPRD1 P41143 1/20 0.34
▸ OPRK1 P41145 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ MCOLN3 Q8TDD5 1/20 0.33
▸ ABCB1 P08183 2/20 0.33
▸ ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173108 1.00 LMNA (0.37) LMNAPOLBCA1CA2MAPT
SCHEMBL2173817 0.85 LMNA (0.41) LMNAPOLBCA1CA2MAPT
SCHEMBL2173598 0.85 LMNA (0.41) LMNAPOLBCA1CA2MAPT
SCHEMBL3458170 0.84 POLB (0.38) LMNAPOLBMAPTTP53ALDH1A1
SCHEMBL3457756 0.84 POLB (0.38) LMNAPOLBMAPTTP53ALDH1A1
SCHEMBL6023715 0.72 POLB (0.38) LMNAPOLBMAPTTP53ALDH1A1
SCHEMBL6024794 0.72 POLB (0.38) LMNAPOLBMAPTTP53ALDH1A1
SCHEMBL1105205 0.68 ALDH1A1 (0.44) LMNAMAPTP2RX7ALDH1A1SMN1; SMN2
SCHEMBL6024693 0.68 BACE1 (0.40) LMNAPOLBALDH1A1
SCHEMBL15968980 0.68 LMNA (0.44) LMNACA1CA2MAPTP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 LMNA 2321/4885POLB 1594/4885CA1 86/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 LMNA 2198/4885POLB 1479/4885CA1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.